Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-15
2011-03-15
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07906486
ABSTRACT:
An immunomodulatory compound is utilized to treat mucosa disease.
REFERENCES:
patent: 4125626 (1978-11-01), Orlowski et al.
patent: 4568489 (1986-02-01), Floyd
patent: 4758551 (1988-07-01), Meister et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4895835 (1990-01-01), Hasegawa
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 5206220 (1993-04-01), Hilton
patent: 5736519 (1998-04-01), Deigin et al.
patent: 5744452 (1998-04-01), Kolobov et al.
patent: 5877147 (1999-03-01), Pinegin
patent: 5888980 (1999-03-01), Ripka
patent: 5916878 (1999-06-01), Kolobov et al.
patent: 6060452 (2000-05-01), Green et al.
patent: 7173013 (2007-02-01), Kolobov et al.
patent: 2002/0177226 (2002-11-01), Kozhemyakin et al.
patent: 2005/0256042 (2005-11-01), Jeffers et al.
patent: 2006/0094665 (2006-05-01), Green
patent: 2007/0087974 (2007-04-01), Tuthill et al.
patent: 2009/0074815 (2009-03-01), Tuthill et al.
patent: 2009/0088392 (2009-04-01), Tuthill et al.
patent: 2009/0143313 (2009-06-01), Mossel et al.
patent: 2010/0204295 (2010-08-01), Kolobov et al.
patent: 1020179 (2000-07-01), None
patent: 2120298 (1998-10-01), None
patent: WO 92/17191 (1992-10-01), None
patent: WO 93/08815 (1993-05-01), None
patent: WO 94/20063 (1994-09-01), None
patent: WO 96/40740 (1996-12-01), None
patent: WO 97/19691 (1997-06-01), None
patent: WO 03/013572 (2003-02-01), None
patent: 2005112639 (2005-12-01), None
patent: WO 2006/047702 (2006-05-01), None
patent: WO 2006/076169 (2006-07-01), None
patent: WO 2006/116053 (2006-11-01), None
patent: WO 2008/076443 (2008-06-01), None
patent: WO 2008/143824 (2008-11-01), None
patent: WO 2009/025830 (2009-02-01), None
patent: WO 2010/017178 (2010-02-01), None
Kian Ang et al. J. Clin. Oncol., 2005, vol. 23, No. 13, pp. 3008-3015.
Cerchietti, Leandro C.A., et al., “Double-Blinded, Placebo-Controlled Trial on Intravenous I-alanyl-I-glutamine in the Incidence of Oral Mucositis following chemoradiotherapy in patients with head-and-neck cancer”, International Journal of Radiation Oncology Biology Physics, vol. 65, No. 5; 2006; p. 1330-1337.
Epstein, J. B., et al., “Emerging Approaches for Prophylaxis and Management of Oropharyngeal Mucositis in Cancer Therapy”, Expert Opinion on Emerging Drugs, vol. 11, No. 2, May 2006, p. 353-373.
Savarese, D., et al., “Prevention of Chemotherapy and radiation toxicity with glutamine”, Cancer Treatment Reviews, vol. 29, Jun. 24, 2003, p. 501-513.
EP08725404 Supplementary European Search Report mailed Mar. 9, 2010.
PCT/US2008/01768 International Search Report mailed Aug. 1, 2008.
PCT/US2008/01768 IPRP and Written Opinion mailed Aug. 27, 2009.
U.S. Appl. No. 12/600,584, Kolobov et al.
U.S. Appl. No. 12/674,646, Tuthill.
International Search Report and Written Opinion for PCT/US08/01768, mailed Aug. 1, 2008.
International Preliminary Report on Patentability for PCT/US08/01768, issued on Aug. 19, 2009.
Database IMSDRUGNEWS, R & D Focus Drug News, XP-002377619, Sep. 6, 1999.
Database CIN, Other Research News, XP-002377620, Feb. 28, 2000.
Database IMSDRUGNEWS, R & D Focus Drug News, XP-002377621, Jan. 22, 2001.
Hasegawa et al., “γ-Glutamylpeptide Formative Activity of Corynebacterium glutamicum by the Reverse Reaction of the γ-Glutamylpeptide Hydrolytic Enzyme,” Agric. Biol. Chem., vol. 42, No. 2, pp. 371-381, (1978).
Hirata et al., “Studies on Separation of Amino Acids and Related Compounds, VIII. Separation of L-Aspartyl-(α,β)-L-histidine and of L-Glutamyl-(α,γ)-L-Histidine,” Bulletin of the Chemical Society of Japan, vol. 45, No. 6, 1972, pp. 1790-1794.
Kian Ang, K. et al., “Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14,” Journal of Clinical Oncology, May 1, 2005, vol. 23, No. 13, pp. 3008-3015.
Li, K. W. et al., “The antinatriuretic Action of γ-L-glutamyl-5-hydroxy-L-tryptophan is dependent on its decarboxylation to 5-hydroxytryptamine in normal man,” Br. J. Clin. Pharmac., 387, pp. 265-269 (1994).
Prezioso et al., “γ-Glutamyltranspeptidase Expression Regulates the Growth-Inhibitory Activity of Anti-Tumor Prodrug γ-L-gultaminyl-4-hydroxy-3-iodobenzene,” Int. J. Cancer, 56, pp. 874-879 (1994).
Smith, D. L. et al., “Natural Killer Cell Cytolytic Activity is Necessary for In Vivo Antitumor Activity of the Dipeptide L-Glutamyl-L-Tryptophan,” Int. J. Cancer, 2003, vol. 106, pp. 528-533.
Wellner, D., “Separation of γ-Glutamyl Amino Acids by Ion-Exchange Chromatography,” Methods in Enzymology, vol. 113, 1985, pp. 564-566.
Rios Israel
Tuthill Cynthia
Anderson James D
Cooley LLP
SciClone Pharmaceuticals Inc.
LandOfFree
Method of treating or preventing tissue deterioration,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or preventing tissue deterioration,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or preventing tissue deterioration,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710806